



Please type a plus sign (+) inside this box →

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/506,598	
			Filing Date	September 2, 2004	
			First Named Inventor	Andreas Meisel	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	BB-117

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/CH/	R1	ALLEWELT M <i>et al.</i> , "Diagnosis and Therapy of Abscess Forming Pneumonia" <i>Therapeutische Umschau. Revue Therapeutique</i> . (2001), vol. 58, pages 599-603.	
/CH/	R2	"Application of a new fluoroquinolone, moxifloxacin (Avalox®) for the treatment of chronic bronchitis" <i>Notfall Medizin</i> (1999), Germany, vol. 25, page 478, XP009013170.	
/CH/	R3	CHRYSOS G E <i>et al.</i> , "Hospital infections in diabetic patients with cerebral stroke" <i>International Journal of Antimicrobial Agents</i> (2001), vol. 17, page S72, XP001152998.	
/CH/	R4	GIROIR BP <i>et al.</i> , "Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis" <i>The Lancet</i> (1997), vol. 350, pages 1439-1443.	
/CH/	R5	Database WPI, Section Ch, Week 199908 Derwent Publications Ltd., London, GB; Class B04, AN 1999-081970 XP002246596 & CN 1194828 A (WANG W).	
/CH/	R6	DAVENPORT R J <i>et al.</i> , "Complications after acute stroke" <i>Stroke Online</i> , vol. 27, pages 415-420, XP002246595.	
/CH/	R7	FONG I W, "Antibiotics Effects in a Rabbit Model of Chlamydia pneumoniae-Induced Atherosclerosis" <i>The Journal of Infectious Diseases</i> (2000), United States, vol. 181, pages S514-S518, XP009013134.	
/CH/	R8	MARTYNOV YU S <i>et al.</i> , "Early and late post stroke pneumonias" <i>Zhurnal nevrologii i Psikiatrii Imeni S S Korsakova</i> , vol. 80, pages 1628-1634, XP009013167.	
/CH/	R9	PANELLA P <i>et al.</i> , "Monitoring of low urinary tract infections in patients hospitalized with neurological diseases" <i>Archivio Italiano di Urologia, Andrologia: Organo Ufficiale di Societa Italiana di Ecografia Urologica E Nefrologica/Associazione Ricerche in Urologia</i> , Italy, December 1994. vol. 66, 259-264, XP009013147.	
/CH/	R10	YRJANHEIKKI J <i>et al.</i> , "A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window" <i>Proceedings of the National Academy of Sciences of the United States</i> (1999), vol. 96, pages 13496-13500, XP002246594.	

Examiner Signature	/Carlic Huynh/	Date Considered	11/26/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M:\Linda\DOC\DS\BB-117-IDS.doc\DNB\j

BEST AVAILABLE COPY



Please type a plus sign (+) in this box ☐

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1448A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/506,598
		Filing Date	September 2, 2004
		First Named Inventor	Andreas Meisel
		Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned	Attorney Docket Number	BB-117
Sheet	1	of	2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (If known)			
	U1					
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Code <sup>2</sup> Office <sup>3</sup> (if known)	Number <sup>4</sup> (if known)				
/CH/	F1		WO 9612500	A	Boehringer Ingelheim International	05-02-1996	
/CH/	F2		WO 0110465	A	Bayer AG	02-15-2001	
	F3						
	F4						
	F5						
	F6						
	F7						
	F8						

Examiner Signature	/Carlic Huynh/	Date Considered	11/26/2007
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.